267 related articles for article (PubMed ID: 21362439)
41. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
42. Comparative evaluation of hERG potassium channel blockade by antipsychotics.
Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2007 Sep; 29(7):457-65. PubMed ID: 17982510
[TBL] [Abstract][Full Text] [Related]
43. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
44. Cell-Based hERG Channel Inhibition Assay in High-Throughput Format.
Zhao J; Xia M
Methods Mol Biol; 2022; 2474():21-28. PubMed ID: 35294752
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.
Chaudhary KW; O'Neal JM; Mo ZL; Fermini B; Gallavan RH; Bahinski A
Assay Drug Dev Technol; 2006 Feb; 4(1):73-82. PubMed ID: 16506891
[TBL] [Abstract][Full Text] [Related]
46. Halide ion effects on human Ether-à-go-go related gene potassium channel properties.
Zeng H; Balasubramanian B; Penniman JR; Kinose F; Salata JJ; Lagrutta A
Assay Drug Dev Technol; 2013; 11(9-10):544-50. PubMed ID: 24147984
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.
Duncan RS; McPate MJ; Ridley JM; Gao Z; James AF; Leishman DJ; Leaney JL; Witchel HJ; Hancox JC
Biochem Pharmacol; 2007 Aug; 74(3):425-37. PubMed ID: 17560554
[TBL] [Abstract][Full Text] [Related]
48. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
[TBL] [Abstract][Full Text] [Related]
49. Observations on conducting whole-cell patch clamping of the hERG cardiac K
Kang J; Luo Y; Searles M; Rampe D
J Appl Toxicol; 2017 Apr; 37(4):445-453. PubMed ID: 27553911
[TBL] [Abstract][Full Text] [Related]
50. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
[TBL] [Abstract][Full Text] [Related]
51. Comparative effects of liensinine and neferine on the human ether-a-go-go-related gene potassium channel and pharmacological activity analysis.
Dong ZX; Zhao X; Gu DF; Shi YQ; Zhang J; Hu XX; Hu MQ; Yang BF; Li BX
Cell Physiol Biochem; 2012; 29(3-4):431-42. PubMed ID: 22508050
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).
Gerlach AC; Stoehr SJ; Castle NA
Mol Pharmacol; 2010 Jan; 77(1):58-68. PubMed ID: 19805508
[TBL] [Abstract][Full Text] [Related]
53. H(1) antihistamine drug promethazine directly blocks hERG K(+) channel.
Jo SH; Hong HK; Chong SH; Lee HS; Choe H
Pharmacol Res; 2009 Nov; 60(5):429-37. PubMed ID: 19497368
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.
Murphy SM; Palmer M; Poole MF; Padegimas L; Hunady K; Danzig J; Gill S; Gill R; Ting A; Sherf B; Brunden K; Stricker-Krongrad A
J Pharmacol Toxicol Methods; 2006; 54(1):42-55. PubMed ID: 16326118
[TBL] [Abstract][Full Text] [Related]
55. The calmodulin inhibitor N-(6-aminohexyl)-5-chloro-1-naphthalene sulphonamide directly blocks human ether à-go-go-related gene potassium channels stably expressed in human embryonic kidney 293 cells.
Zhang XH; Jin MW; Sun HY; Zhang S; Li GR
Br J Pharmacol; 2010 Oct; 161(4):872-84. PubMed ID: 20860665
[TBL] [Abstract][Full Text] [Related]
56. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
Louvel J; Carvalho JF; Yu Z; Soethoudt M; Lenselink EB; Klaasse E; Brussee J; Ijzerman AP
J Med Chem; 2013 Dec; 56(23):9427-40. PubMed ID: 24224763
[TBL] [Abstract][Full Text] [Related]
57. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
[TBL] [Abstract][Full Text] [Related]
58. Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel.
Houtmann S; Schombert B; Sanson C; Partiseti M; Bohme GA
Methods Mol Biol; 2017; 1641():187-199. PubMed ID: 28748465
[TBL] [Abstract][Full Text] [Related]
59. Curcumin inhibits hERG potassium channels in vitro.
Hu CW; Sheng Y; Zhang Q; Liu HB; Xie X; Ma WC; Huo R; Dong DL
Toxicol Lett; 2012 Jan; 208(2):192-6. PubMed ID: 22101212
[TBL] [Abstract][Full Text] [Related]
60. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Nogawa H; Kawai T
Eur J Pharmacol; 2014 Oct; 741():336-9. PubMed ID: 24998878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]